Breaking News, Collaborations & Alliances

FogPharma, ARTBIO Partner to Develop Helicon-Enabled ARTs (HEARTs)

Aim to transform outcomes for patients with multiple types of cancer.

Author Image

By: Charlie Sternberg

Associate Editor

FogPharma, a clinical-stage biopharmaceutical company dedicated to delivering a new class of therapies that go beyond the limits of currently available medicines using its Helicon peptide platform, and ARTBIO Inc., a clinical-stage radiopharmaceutical company developing a new class of 212Pb alpha radioligand therapies (ARTs), have partnered to co-develop Helicon-enabled ARTs (HEARTs) to transform outcomes for patients with multiple types of cancer.   ARTBIO and FogPharma will co-develop novel ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters